EMBLA — Embla Medical hf Share Price
0.000.00%
Last trade - 00:00- DKK12.48bn
- DKK15.85bn
- $785.68m
- 73
- 22
- 69
- 56
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 21.25 | ||
| PEG Ratio (f) | 0.98 | ||
| EPS Growth (f) | 27.72% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.45 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 38.38 | ||
| Price to Sales | 2.23 | ||
| EV to EBITDA | 16.27 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 6.78% | ||
| Return on Equity | 8.25% | ||
| Operating Margin | 11.07% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 686.26 | 629.5 | 718.67 | 718.65 | 785.68 | 871.75 | 948.5 | 5.09% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -8.85 | -76.36 | +276.2 | -32.87 | +36.53 | +35.33 | +15.96 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Embla Medical hf, formerly Ossur hf, is an Iceland-based company that operates within the field of medical equipment and supplies sector. The Company is active in the development and distribution of products in the fields of non-invasive prosthetics, medical braces and supports. The Company's business activities are divided into three business segment: The Prosthetics, its product portfolio includes a range of lower and upper limb prosthetic components; The Bracing & Supports, which offers the Unloader One range of knee braces that relieve pain from knee osteoarthritis, as well as the Unloader Hip which is designed to reduce pain by optimizing load dispersion for patients suffering from mild and moderate osteoarthritis of the hip; and The Patient Care, which operates a network of Patient Care clinics around the world, with each one catering to individual patients and their needs.
Directors
- Niels Jacobsen CHM (64)
- Jon Sigurdsson PRE (66)
- Svafa Groenfeldt VCH (57)
- Sveinn Solvason CFO (44)
- Margret Fridriksdottir EVP (44)
- Olafur Gylfason EVP (53)
- Egill Jonsson EVP (65)
- Gudjon Karason EVP (53)
- Kristleifur Kristjansson EVP (67)
- Christian Robinson EVP (40)
- Arne Boye Nielsen DRC (54)
- Gudbjorg Eggertsdottir IND (71)
- Alberto Esquenazi IND (65)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- February 16th, 1971
- Public Since
- January 1st, 2009
- No. of Shareholders
- 4,675
- No. of Employees
- 3,999
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange - Copenhagen
- Shares in Issue
- 427,298,353
- Address
- Grjothals 5, REYKJAVIK, 110
- Web
- https://www.emblamedical.com/
- Phone
- +354 5151300
- Contact
- David Hreidarsson
- Auditors
- PricewaterhouseCoopers hf
Upcoming Events for EMBLA
Q3 2024 Ossur hf Earnings Release
Similar to EMBLA
Ambu A/S
OMX Nordic Exchange - Copenhagen
Bactiquant A/S
OMX Nordic Exchange - Copenhagen
BioPorto A/S
OMX Nordic Exchange - Copenhagen
ChemoMetec A/S
OMX Nordic Exchange - Copenhagen
Coloplast A/S
OMX Nordic Exchange - Copenhagen
FAQ
What is the Embla Medical hf share price?
As of Today at 19:07 UTC, shares in Embla Medical hf are trading at DKK29.20. This share price information is delayed by 15 minutes.
How has the Embla Medical hf share price performed this year?
Shares in Embla Medical hf last closed at DKK29.20 and the price had moved by -7.59% over the past 365 days. In terms of relative price strength the Embla Medical hf share price has underperformed the FTSE Global All Cap Index by -15.35% over the past year.
What are the analyst and broker recommendations for Embla Medical hf?
The overall consensus recommendation for Embla Medical hf is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Embla Medical hf dividend yield?
Embla Medical hf does not currently pay a dividend.
Does Embla Medical hf pay a dividend?
Embla Medical hf does not currently pay a dividend.
When does Embla Medical hf next pay dividends?
Embla Medical hf does not currently pay a dividend.
How do I buy Embla Medical hf shares?
To buy shares in Embla Medical hf you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Embla Medical hf?
As of the previous close price of DKK29.20, shares in Embla Medical hf had a market capitalisation of DKK12.48bn.
Where are Embla Medical hf shares listed?
Here are the trading details for Embla Medical hf:
- Country of listing: Denmark
- Exchange: CPH
- Ticker Symbol: EMBLA
What kind of share is Embla Medical hf?
Based on an overall assessment of its quality, value and momentum Embla Medical hf is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Embla Medical hf share price forecast for 2024?
The analyst consensus target price for shares in Embla Medical hf is DKK35.30. That is 20.91% above the last closing price of DKK29.20.
Analysts covering Embla Medical hf currently have a consensus Earnings Per Share (EPS) forecast of $0.19 for the next financial year.
What is the trend in the Embla Medical hf share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Embla Medical hf. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -4.58%.
As of the last closing price of DKK29.20, shares in Embla Medical hf were trading -2.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Embla Medical hf PE Ratio?
The Embla Medical hf PE ratio based on its reported earnings over the past 12 months is 21.25. The shares last closed at DKK29.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Embla Medical hf?
Embla Medical hf's management team is headed by:
- Niels Jacobsen - CHM
- Jon Sigurdsson - PRE
- Svafa Groenfeldt - VCH
- Sveinn Solvason - CFO
- Margret Fridriksdottir - EVP
- Olafur Gylfason - EVP
- Egill Jonsson - EVP
- Gudjon Karason - EVP
- Kristleifur Kristjansson - EVP
- Christian Robinson - EVP
- Arne Boye Nielsen - DRC
- Gudbjorg Eggertsdottir - IND
- Alberto Esquenazi - IND